EGFR and lung carcinoma: Although Osimertinib, the third generation of EGFR-TKI, was employed to address lung cancer with the T790M mutation and has shown excellent effectiveness in this setting, the acquired resistance to the third generation of EGFR-TKI, which involves the cysteine residue at codon 797, has been observed.